凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
华兰生物(002007)公告正文

华兰生物:2014年第三季度报告全文

公告日期 2014-10-31
股票简称:华兰生物 股票代码:002007
                华兰生物工程股份有限公司 2014 年第三季度报告全文华兰生物工程股份有限公司
    2014 年第三季度报告
      2014 年 10 月
                                                   华兰生物工程股份有限公司 2014 年第三季度报告全文
                                  第一节 重要提示
    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
    所有董事均已出席了审议本次季报的董事会会议。
    公司负责人安康、主管会计工作负责人谢军民及会计机构负责人(会计主管人员)王建体声明:保证季度报告中财务报表的真实、准确、完整。
                                                                       华兰生物工程股份有限公司 2014 年第三季度报告全文
                              第二节 主要财务数据及股东变化一、主要会计数据和财务指标公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据□ 是 √ 否
                                       本报告期末                        上年度末                本报告期末比上年度末增减
    总资产(元)                                 3,753,572,864.94               3,643,315,938.55                          3.03%归属于上市公司股东的净资产
                                             3,286,609,740.40               3,077,410,568.75                          6.80%(元)
                                                        本报告期比上年同期                               年初至报告期末比上
                                    本报告期                                       年初至报告期末
                                                                增减                                        年同期增减
    营业收入(元)                       438,860,589.99                    27.88%          967,776,288.11                14.03%归属于上市公司股东的净利润
                                     137,043,338.14                    14.61%          422,644,501.65                20.56%(元)归属于上市公司股东的扣除非经
                                     126,199,692.71                    29.31%          352,578,632.57                13.65%常性损益的净利润(元)经营活动产生的现金流量净额
                                        --                       --                    319,802,594.73                10.37%(元)
    基本每股收益(元/股)                          0.2359                  13.69%                   0.7275               19.58%
    稀释每股收益(元/股)                          0.2359                  13.69%                   0.7275               19.58%
    加权平均净资产收益率                           4.29%                    0.07%                   13.16%                0.43%非经常性损益项目和金额√ 适用 □ 不适用
                                                                                                                    单位:元
                           项目                                 年初至报告期期末金额                        说明
    非流动资产处置损益(包括已计提资产减值准备的冲销部分)                            470,913.53计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                                45,926,014.61一标准定额或定量享受的政府补助除外)
    除上述各项之外的其他营业外收入和支出                                              872,893.75
    其他符合非经常性损益定义的损益项目                                              37,273,817.07
    减:所得税影响额                                                                12,431,183.57
       少数股东权益影响额(税后)                                                2,046,586.31
    合计                                                                            70,065,869.08                --对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
                                                                   华兰生物工程股份有限公司 2014 年第三季度报告全文说明原因□ 适用 √ 不适用公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益项目界定为经常性损益的项目的情形。二、报告期末股东总数及前十名股东持股情况表1、报告期末普通股股东总数及前十名普通股股东持股情况表
                                                                                                                   单位:股
    报告期末普通股股东总数                                                                                              47,440
                                               前 10 名普通股股东持股情况
                                                      持股比                  持有有限售条件         质押或冻结情况
             股东名称                  股东性质                 持股数量
                                                        例                      的股份数量       股份状态       数量
    新乡市华兰生物技术有限公司          境内非国有法人     17.67% 102,723,822                    0
    新乡市金康生物科技开发有限公司 境内非国有法人          15.13%   87,961,115                   0
    香港科康有限公司                    境外法人           13.23% 76,889,088                     0
    新乡市世辰生物技术有限公司          境内非国有法人      3.66%   21,247,640                   0中国工商银行-汇添富均衡增长股
                                    境内非国有法人      1.55%    8,999,947                   0票型证券投资基金兴业银行股份有限公司-兴全趋势
                                    境内非国有法人      1.23%    7,130,124                   0投资混合型证券投资基金中国工商银行股份有限公司-汇添
                                    境内非国有法人      1.20%    6,999,996                   0富医药保健股票型证券投资基金
    全国社保基金一一零组合              境内非国有法人      0.91%    5,306,394                   0中国建设银行-银华核心价值优选
                                    境内非国有法人      0.77%    4,499,831                   0股票型证券投资基金中国银行-大成财富管理 2020 生命
                                    境内非国有法人      0.66%    3,812,837                   0周期证券投资基金
                                       前 10 名无限售条件普通股股东持股情况
                                                             持有无限售条件普通股股                  股份种类
                         股东名称
                                                                     份数量                  股份种类           数量
    新乡市华兰生物技术有限公司                                                   102,723,822 人民币普通股           102,723,822
    新乡市金康生物科技开发有限公司                                                87,961,115 人民币普通股            87,961,115
    香港科康有限公司                                                              76,889,088 人民币普通股            76,889,088
    新乡市世辰生物技术有限公司                                                    21,247,640 人民币普通股            21,247,640
    中国工商银行-汇添富均衡增长股票型证券投资基金                                 8,999,947 人民币普通股             8,999,947
                                                               华兰生物工程股份有限公司 2014 年第三季度报告全文
    兴业银行股份有限公司-兴全趋势投资混合型证券投资基金                   7,130,124 人民币普通股        7,130,124中国工商银行股份有限公司-汇添富医药保健股票型证券投
                                                                       6,999,996 人民币普通股        6,999,996资基金
    全国社保基金一一零组合                                                 5,306,394 人民币普通股        5,306,394
    中国建设银行-银华核心价值优选股票型证券投资基金                       4,499,831 人民币普通股        4,499,831
    中国银行-大成财富管理 2020 生命周期证券投资基金                       3,812,837 人民币普通股        3,812,837
                                                         上述第一、二、三、四股东存在关联关系,属于一致行动人。
                                                         中国工商银行-汇添富均衡增长股票型证券投资基金和中国
    上述股东关联关系或一致行动的说明                         工商银行-汇添富医药保健股票型证券投资基金同为汇添富
                                                         基金管理有限公司旗下基金,未知其他股东之间是否存在关
                                                         联关系,是否属于一致行动人。前 10 名无限售条件普通股股东参与融资融券业务股东情况说
                                                         无明(如有)公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易□ 是 √ 否公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。2、报告期末优先股股东总数及前十名优先股股东持股情况表□ 适用 √ 不适用
                                                                华兰生物工程股份有限公司 2014 年第三季度报告全文
                                           第三节 重要事项一、报告期主要会计报表项目、财务指标发生变动的情况及原因√ 适用 □ 不适用1、报告期末,应收票据期末余额较期初余额减少36.81%,主要是公司票据背书或到期结算所致。2、报告期末,应收账款期末余额较期初余额增加51.18%,主要是公司销售货款尚未到结算期所致。3、报告期末,其他应收款期末余额较期初余额增加1143.19%,主要是本公司支付土地款所致。4、报告期末,其他非流动资产期末余额较期初余额减少100%,主要是公司部分理财产品到期所致。5、报告期末,短期借款期末余额较期初余额减少60%,主要是本公司之子公司华兰生物工程重庆有限公司偿还到期借款所致。6、报告期末,应付账款期末余额较期初余额减少36.62%,主要是支付工程款所致。7、报告期末,预收款项期末余额较期初余额减少60.02%,主要是预收货款已发货并确认收入所致。8、报告期末,应交税费期末余额较期初余额减少46.36%,主要是缴纳所得税所致。9、报告期末,其他应付款期末余额较期初余额增加66.81%,主要一是本公司分红款部分尚未支付;二是本公司之子公司华兰生物疫苗有限公司预提销售费用所致。10、本报告期,营业外收入较上年同期增加427.08%,主要是公司收到政府补助增加所致。二、重要事项进展情况及其影响和解决方案的分析说明□ 适用 √ 不适用三、公司或持股 5%以上股东在报告期内发生或以前期间发生但持续到报告期内的承诺事项√ 适用 □ 不适用
       承诺事由     承诺方                       承诺内容                         承诺时间     承诺期限   履行情况
    股改承诺            不适用 不适用                                                             不适用      不适用收购报告书或权益
    变动报告书中所作 不适用 不适用                                                                不适用      不适用承诺资产重组时所作承
                    不适用 不适用                                                             不适用      不适用诺
                             为避免同业竞争引起的损害本公司及其他股东利益,本
                             公司实际控制人安康先生承诺:"作为本公司实际控制人
    首次公开发行或再 实际控                                                          2004 年 06               正在严格
                             期间,不在与本公司构成同业竞争的其他公司任职,在                 长期有效
    融资时所作承诺      制人                                                         月 25 日                 履行中
                             其经营业务中将不会利用其在本公司及本公司股东中的
                             地位从事任何有损本公司及其他股东利益的行为。
                           公司未来三年(2012-2014 年)的具体股东回报规划:1、
    其他对公司中小股                                                              2012 年 08      2012-2014   正在严格
                    董事会 公司可以采取现金、股票、现金与股票相结合或者法律、
    东所作承诺                                                                    月 29 日        年          履行中
                           法规允许的其他方式分配利润。2、根据《公司法》等有
                                                             华兰生物工程股份有限公司 2014 年第三季度报告全文
                          关法律法规及《公司章程》的规定,在公司盈利且现金
                          能够满足公司持续经营和长期发展、符合现金分红条件
                          的前提下,2012-2014 年每年以现金方式分配的利润应不
                          低于当年实现的可分配利润的 10%,且连续三年内以现
                          金方式累计分配的利润不少于该三年实现的年均可分配
                          利润的 30%。 3、未来三年(2012-2014 年)公司原则
                          上每年度进行一次现金分红,公司董事会可以根据公司
                          盈利情况及资金需求状况提议公司进行中期现金分红。
                          4、未来三年(2012-2014)公司可以根据累计可供分配
                          利润、公积金及现金流状况,在保证最低现金分红比例
                          和公司股本规模合理的前提下,为保持股本扩张与业绩
                          增长相适应,公司可以采取股票股利方式进行利润分配,
                          具体分红比例由公司董事会审议通过后,并提交股东大
                          会审议决定。承诺是否及时履行 是未完成履行的具体原因及下一步计划 不适用(如有)四、对 2014 年度经营业绩的预计2014 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    2014 年度归属于上市公司股东的净利润变动幅度                          0.00%     至                     30.00%
    2014 年度归属于上市公司股东的净利润变动区间(万元)             47,533.75      至                   61,793.87
    2013 年度归属于上市公司股东的净利润(万元)                                                         47,533.75
                                                      公司预计 2014 年度归属于上市公司股东的净利润同比增加
    业绩变动的原因说明                                    0%-30%,主要原因是公司销售收入及非经常性损益较上年同
                                                      期增长所致。五、证券投资情况□ 适用 √ 不适用公司报告期不存在证券投资。持有其他上市公司股权情况的说明□ 适用 √ 不适用公司报告期未持有其他上市公司股权。六、新颁布或修订的会计准则对公司合并财务报表的影响□ 适用 √ 不适用
                                                         华兰生物工程股份有限公司 2014 年第三季度报告全文
                                     第四节 财务报表一、财务报表1、合并资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                    单位:元
                 项目                    期末余额                                期初余额流动资产:
    货币资金                                         970,469,310.88                         1,035,311,503.25
    结算备付金
    拆出资金
    以公允价值计量且其变动计入当期损益的金融资产
    应收票据                                          39,594,624.91                           62,661,861.40
    应收账款                                         258,077,452.75                          170,710,176.97
    预付款项                                          86,829,252.88                           82,845,091.05
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款                                        31,193,840.55                            2,509,171.20
    买入返售金融资产
    存货                                             415,372,796.47                          342,588,796.14
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                     790,000,000.00                          658,000,000.00
    流动资产合计                                        2,591,537,278.44                        2,354,626,600.01非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
                                        华兰生物工程股份有限公司 2014 年第三季度报告全文
    长期应收款
    长期股权投资                     38,882,408.92                         40,094,602.70
    投资性房地产
    固定资产                        757,452,103.39                        807,062,269.33
    在建工程                        203,014,183.63                        184,340,318.65
    工程物资
    固定资产清理
    生产性生物资产                    2,402,539.56                          1,961,961.02
    油气资产
    无形资产                        139,375,910.80                        135,855,861.74
    开发支出
    商誉
    长期待摊费用                      3,328,883.00                          3,444,439.00
    递延所得税资产                   17,579,557.20                         15,929,886.10
    其他非流动资产                                                        100,000,000.00
    非流动资产合计                     1,162,035,586.50                     1,288,689,338.54
    资产总计                           3,753,572,864.94                     3,643,315,938.55流动负债:
    短期借款                         60,000,000.00                        150,000,000.00
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据
    应付账款                         52,634,607.20                         83,051,891.60
    预收款项                          4,748,357.26                         11,877,134.01
    卖出回购金融资产款
    应付手续费及佣金
    应付职工薪酬                        773,368.84                           264,598.18
    应交税费                         15,623,602.69                         29,125,221.57
    应付利息
    应付股利
    其他应付款                       97,137,074.08                         58,231,319.85
                                                          华兰生物工程股份有限公司 2014 年第三季度报告全文
    应付分保账款
    保险合同准备金
    代理买卖证券款
    代理承销证券款
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                                          230,917,010.07                        332,550,165.21非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                                              230,917,010.07                        332,550,165.21所有者权益(或股东权益):
    实收资本(或股本)                               581,304,800.00                        580,914,800.00
    资本公积                                         367,109,652.03                        348,611,062.03
    减:库存股
    专项储备
    其他综合收益
    盈余公积                                         247,742,357.39                        247,742,357.39
    一般风险准备
    未分配利润                                      2,090,452,930.98                     1,900,142,349.33
    归属于母公司所有者权益合计                           3,286,609,740.40                     3,077,410,568.75
    少数股东权益                                     236,046,114.47                        233,355,204.59
    所有者权益(或股东权益)合计                         3,522,655,854.87                     3,310,765,773.34负债和所有者权益(或股东权益)总
                                                     3,753,572,864.94                     3,643,315,938.55计
    法定代表人:安康                   主管会计工作负责人:谢军民                     会计机构负责人:王建体
                                                     华兰生物工程股份有限公司 2014 年第三季度报告全文2、母公司资产负债表编制单位:华兰生物工程股份有限公司
                                                                                                单位:元
                 项目                期末余额                                期初余额流动资产:
    货币资金                                     502,886,607.33                          690,546,554.50
    以公允价值计量且其变动计入当期损益的金融资产
    应收票据                                      36,332,124.91                           23,436,200.00
    应收账款                                      48,401,136.48                           55,034,074.75
    预付款项                                      76,434,701.85                           45,515,855.68
    应收利息
    应收股利
    其他应收款                                    62,629,817.88                          110,933,905.48
    存货                                         206,074,163.37                          203,202,794.70
    划分为持有待售的资产
    一年内到期的非流动资产
    其他流动资产                                 690,000,000.00                          295,000,000.00
    流动资产合计                                    1,622,758,551.82                        1,423,669,385.11非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款                                     5,379,060.00                            5,379,060.00
    长期股权投资                                 641,749,106.03                          642,961,299.81
    投资性房地产
    固定资产                                     196,837,220.99                          213,083,308.47
    在建工程                                     171,534,268.01                          173,308,464.61
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                      63,137,696.42                           65,026,217.09
    开发支出
    商誉
                                        华兰生物工程股份有限公司 2014 年第三季度报告全文
    长期待摊费用                      3,328,883.00                          3,444,439.00
    递延所得税资产                    3,489,703.36                          3,489,703.36
    其他非流动资产                                                        100,000,000.00
    非流动资产合计                     1,085,455,937.81                     1,206,692,492.34
    资产总计                           2,708,214,489.63                     2,630,361,877.45流动负债:
    短期借款
    以公允价值计量且其变动计入当期损益的金融负债
    应付票据
    应付账款                         22,716,025.67                         63,485,898.37
    预收款项                          2,805,151.00                          3,500,858.00
    应付职工薪酬                        587,670.96                           156,336.00
    应交税费                          8,255,624.41                         21,123,726.59
    应付利息
    应付股利
    其他应付款                       28,750,445.37                           276,771.90
    划分为持有待售的负债
    一年内到期的非流动负债
    其他流动负债
    流动负债合计                         63,114,917.41                         88,543,590.86非流动负债:
    长期借款
    应付债券
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债非流动负债合计
    负债合计                             63,114,917.41                         88,543,590.86所有者权益(或股东权益):
    实收资本(或股本)              581,304,800.00                        580,914,800.00
    资本公积                        375,857,449.54                        357,358,859.54
                                                               华兰生物工程股份有限公司 2014 年第三季度报告全文
    减:库存股
    专项储备
    其他综合收益
    盈余公积                                              247,742,357.39                          247,742,357.39
    一般风险准备
    未分配利润                                           1,440,194,965.29                        1,355,802,269.66
    所有者权益(或股东权益)合计                              2,645,099,572.22                        2,541,818,286.59负债和所有者权益(或股东权益)总
                                                          2,708,214,489.63                        2,630,361,877.45计
    法定代表人:安康                     主管会计工作负责人:谢军民                        会计机构负责人:王建体3、合并本报告期利润表编制单位:华兰生物工程股份有限公司
                                                                                                          单位:元
                  项目                         本期金额                                上期金额
    一、营业总收入                                             438,860,589.99                          343,189,136.15
    其中:营业收入                                        438,860,589.99                          343,189,136.15
          利息收入
          已赚保费
          手续费及佣金收入
    二、营业总成本                                             286,570,035.02                          233,122,470.96
    其中:营业成本                                        179,639,224.29                          145,148,192.03
          利息支出
          手续费及佣金支出
          退保金
          赔付支出净额
          提取保险合同准备金净额
          保单红利支出
          分保费用
          营业税金及附加                                     1,990,789.89                            3,163,864.09
          销售费用                                          41,064,817.36                           33,745,227.38
          管理费用                                          56,844,413.52                           33,003,710.18
          财务费用                                           -5,876,500.98                             340,923.64
          资产减值损失                                      12,907,290.94                           17,720,553.64
                                                                华兰生物工程股份有限公司 2014 年第三季度报告全文
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                              9,345,659.15                         20,896,063.94填列)
             其中:对联营企业和合营
                                                               -938,162.55企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                          161,636,214.12                        130,962,729.13
       加   :营业外收入                                      2,215,438.47                          4,598,021.68
       减   :营业外支出                                         38,493.13                           246,175.81
             其中:非流动资产处置损
                                                                 16,138.41                             19,956.32失四、利润总额(亏损总额以“-”号填
                                                            163,813,159.46                        135,314,575.00列)
       减:所得税费用                                        20,051,092.65                         16,181,415.84
    五、净利润(净亏损以“-”号填列)                          143,762,066.81                        119,133,159.16
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                           137,043,338.14                        119,575,446.51
       少数股东损益                                           6,718,728.67                           -442,287.35
    六、每股收益:                                        --                                   --
       (一)基本每股收益                                             0.2359                             0.2075
       (二)稀释每股收益                                             0.2359                             0.2075七、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    八、综合收益总额                                            143,762,066.81                        119,133,159.16
       归属于母公司所有者的综合收益
                                                            137,043,338.14                        119,575,446.51总额
       归属于少数股东的综合收益总额                           6,718,728.67                           -442,287.35
    法定代表人:安康                         主管会计工作负责人:谢军民                     会计机构负责人:王建体
                                                      华兰生物工程股份有限公司 2014 年第三季度报告全文4、母公司本报告期利润表编制单位:华兰生物工程股份有限公司
                                                                                               单位:元
                 项目                   本期金额                              上期金额
    一、营业收入                                       211,862,443.52                        166,610,246.36
       减:营业成本                                 77,231,964.60                         54,524,939.04
           营业税金及附加                             952,382.15                           1,409,393.94
           销售费用                                  5,479,773.48                          1,452,350.28
           管理费用                                 29,958,622.56                          8,845,286.32
           财务费用                                 -5,901,174.28                         -2,275,774.86
           资产减值损失                                -92,709.06
       加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填
                                                     4,020,741.56                         13,956,095.90列)
           其中:对联营企业和合营企
                                                      -938,162.55业的投资收益
    二、营业利润(亏损以“-”号填列)                 108,254,325.63                        116,610,147.54
       加:营业外收入                                 558,263.28                             -44,183.62
       减:营业外支出                                     695.00                            171,564.15
           其中:非流动资产处置损失                       245.00                              10,641.32三、利润总额(亏损总额以“-”号填
                                                   108,811,893.91                        116,394,399.77列)
       减:所得税费用                               17,476,611.36                         17,511,775.33
    四、净利润(净亏损以“-”号填列)                  91,335,282.55                         98,882,624.44
    五、每股收益:                             --                                    --
       (一)基本每股收益
       (二)稀释每股收益六、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    七、综合收益总额                                    91,335,282.55                         98,882,624.44
                                                                 华兰生物工程股份有限公司 2014 年第三季度报告全文
    法定代表人:安康                         主管会计工作负责人:谢军民                      会计机构负责人:王建体5、合并年初到报告期末利润表编制单位:华兰生物工程股份有限公司
                                                                                                          单位:元
                   项目                            本期金额                              上期金额
    一、营业总收入                                                967,776,288.11                        848,670,508.60
       其中:营业收入                                         967,776,288.11                        848,670,508.60
             利息收入
             已赚保费
             手续费及佣金收入
    二、营业总成本                                                547,026,513.45                        482,927,518.13
       其中:营业成本                                         357,149,389.69                        325,844,285.78
             利息支出
             手续费及佣金支出
             退保金
             赔付支出净额
             提取保险合同准备金净额
             保单红利支出
             分保费用
             营业税金及附加                                     6,760,675.83                          6,763,335.07
             销售费用                                          47,998,896.11                         40,527,236.60
             管理费用                                         136,976,519.90                        106,792,764.95
             财务费用                                         -22,125,239.31                        -19,922,790.30
             资产减值损失                                      20,266,271.23                         22,922,686.03
       加   :公允价值变动收益(损失以“-”号填列)
             投资收益(损失以“-”号
                                                               29,313,817.08                         36,033,721.95填列)
             其中:对联营企业和合营
                                                               -1,212,193.78企业的投资收益
             汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                            450,063,591.74                        401,776,712.42
       加   :营业外收入                                       47,525,403.66                          9,016,663.54
                                                               华兰生物工程股份有限公司 2014 年第三季度报告全文
       减   :营业外支出                                       255,581.77                            593,596.75
             其中:非流动资产处置损
                                                               114,649.08                              32,003.52失四、利润总额(亏损总额以“-”号填
                                                         497,333,413.63                           410,199,779.21列)
       减:所得税费用                                        71,998,002.10                         63,246,669.78
    五、净利润(净亏损以“-”号填列)                       425,335,411.53                           346,953,109.43
       其中:被合并方在合并前实现的净利润
       归属于母公司所有者的净利润                        422,644,501.65                           350,571,619.76
       少数股东损益                                           2,690,909.88                         -3,618,510.33
    六、每股收益:                                     --                                     --
       (一)基本每股收益                                          0.7275                                0.6084
       (二)稀释每股收益                                          0.7275                                0.6084七、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    八、综合收益总额                                         425,335,411.53                           346,953,109.43
       归属于母公司所有者的综合收益
                                                         422,644,501.65                           350,571,619.76总额
       归属于少数股东的综合收益总额                           2,690,909.88                         -3,618,510.33
    法定代表人:安康                      主管会计工作负责人:谢军民                       会计机构负责人:王建体6、母公司年初到报告期末利润表编制单位:华兰生物工程股份有限公司
                                                                                                        单位:元
                       项目                       本期金额                             上期金额
    一、营业收入                                             584,203,146.81                           466,373,114.22
       减:营业成本                                      213,721,975.03                           159,278,827.21
            营业税金及附加                                    4,068,159.59                          3,905,559.57
            销售费用                                          8,666,502.69                          2,658,458.52
            管理费用                                         56,740,931.14                         27,488,627.65
                                                                    华兰生物工程股份有限公司 2014 年第三季度报告全文
           财务费用                                              -23,469,491.68                        -24,602,201.80
           资产减值损失                                             936,450.80                           1,017,871.01
    加:公允价值变动收益(损失以“-”号填列)
           投资收益(损失以“-”号填列)                         12,236,446.78                         18,692,637.00
           其中:对联营企业和合营企业的投
                                                                  -1,212,193.78资收益
    二、营业利润(亏损以“-”号填列)                               335,775,066.02                        315,318,609.06
    加:营业外收入                                               35,153,962.61                           849,925.58
    减:营业外支出                                                 102,416.75                            184,171.35
           其中:非流动资产处置损失                                   96,456.33                             22,688.52
    三、利润总额(亏损总额以“-”号填列)                           370,826,611.88                        315,984,363.29
    减:所得税费用                                               54,099,996.25                         47,450,269.86
    四、净利润(净亏损以“-”号填列)                               316,726,615.63                        268,534,093.43
    五、每股收益:                                              --                                 --
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益其中:以后会计期间不能重分类进损益的其他综合收益项目
         以后会计期间在满足规定条件时将重分类进损益的其他综合收益项目
    七、综合收益总额                                                 316,726,615.63                        268,534,093.43
    法定代表人:安康                            主管会计工作负责人:谢军民                      会计机构负责人:王建体7、合并年初到报告期末现金流量表编制单位:华兰生物工程股份有限公司
                                                                                                             单位:元
                 项目                                 本期金额                              上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                                901,377,837.17                        790,738,878.21
    客户存款和同业存放款项净增加额
    向中央银行借款净增加额
    向其他金融机构拆入资金净增加
                                       华兰生物工程股份有限公司 2014 年第三季度报告全文额
    收到原保险合同保费取得的现金
    收到再保险业务现金净额
    保户储金及投资款净增加额
    处置交易性金融资产净增加额
    收取利息、手续费及佣金的现金
    拆入资金净增加额
    回购业务资金净增加额
    收到的税费返还
    收到其他与经营活动有关的现金    80,082,055.45                        48,919,195.75
    经营活动现金流入小计                981,459,892.62                       839,658,073.96
    购买商品、接受劳务支付的现金   317,179,516.69                       283,653,954.18
    客户贷款及垫款净增加额
    存放中央银行和同业款项净增加额
    支付原保险合同赔付款项的现金
    支付利息、手续费及佣金的现金
    支付保单红利的现金
    支付给职工以及为职工支付的现
                                     88,932,910.05                        78,565,476.38金
    支付的各项税费                 161,072,077.49                       103,246,007.58
    支付其他与经营活动有关的现金    94,472,793.66                        84,448,329.13
    经营活动现金流出小计                661,657,297.89                       549,913,767.27
    经营活动产生的现金流量净额          319,802,594.73                       289,744,306.69二、投资活动产生的现金流量:
    收回投资收到的现金             570,108,333.34                       894,000,000.00
    取得投资收益所收到的现金        30,526,010.86                        36,033,721.95
    处置固定资产、无形资产和其他
                                       172,500.00                             64,500.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                600,806,844.20                       930,098,221.95
    购建固定资产、无形资产和其他
                                     86,436,851.75                       134,891,576.24长期资产支付的现金
                                                                华兰生物工程股份有限公司 2014 年第三季度报告全文
       投资支付的现金                                       600,000,000.00                         659,000,000.00
       质押贷款净增加额
       取得子公司及其他营业单位支付的现金净额
       支付其他与投资活动有关的现金                                                                200,000,000.00
    投资活动现金流出小计                                        686,436,851.75                         993,891,576.24
    投资活动产生的现金流量净额                                   -85,630,007.55                        -63,793,354.29三、筹资活动产生的现金流量:
       吸收投资收到的现金                                     6,157,000.00                          57,414,900.00
       其中:子公司吸收少数股东投资收到的现金
       取得借款收到的现金                                                                          140,000,000.00
       发行债券收到的现金
       收到其他与筹资活动有关的现金
    筹资活动现金流入小计                                          6,157,000.00                         197,414,900.00
       偿还债务支付的现金                                    90,000,000.00                         120,000,000.00
       分配股利、利润或偿付利息支付
                                                            207,770,848.32                          63,357,146.64的现金
       其中:子公司支付给少数股东的股利、利润
       支付其他与筹资活动有关的现金                             943,200.00
    筹资活动现金流出小计                                        298,714,048.32                         183,357,146.64
    筹资活动产生的现金流量净额                                 -292,557,048.32                          14,057,753.36四、汇率变动对现金及现金等价物的
                                                                 -36,945.90                            -25,160.33影响
    五、现金及现金等价物净增加额                                 -58,421,407.04                        239,983,545.43
       加:期初现金及现金等价物余额                        1,027,260,672.95                        744,501,536.95
    六、期末现金及现金等价物余额                                968,839,265.91                         984,485,082.38
    法定代表人:安康                      主管会计工作负责人:谢军民                        会计机构负责人:王建体8、母公司年初到报告期末现金流量表编制单位:华兰生物工程股份有限公司
                                                                                                         单位:元
                 项目                           本期金额                                上期金额一、经营活动产生的现金流量:
                                        华兰生物工程股份有限公司 2014 年第三季度报告全文
    销售商品、提供劳务收到的现金   604,969,162.09                        556,533,226.52
    收到的税费返还
    收到其他与经营活动有关的现金   143,535,330.79                         28,698,108.20
    经营活动现金流入小计                748,504,492.88                        585,231,334.72
    购买商品、接受劳务支付的现金   196,563,407.87                        182,466,477.43
    支付给职工以及为职工支付的现
                                     25,439,125.92                         25,343,229.05金
    支付的各项税费                 105,554,839.99                         63,107,832.61
    支付其他与经营活动有关的现金    55,920,962.20                         29,384,410.25
    经营活动现金流出小计                383,478,335.98                        300,301,949.34
    经营活动产生的现金流量净额          365,026,156.90                        284,929,385.38二、投资活动产生的现金流量:
    收回投资收到的现金             205,000,000.00                        695,000,000.00
    取得投资收益所收到的现金        13,448,640.56                         18,692,637.00
    处置固定资产、无形资产和其他
                                        170,000.00                           214,500.00长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
    收到其他与投资活动有关的现金
    投资活动现金流入小计                218,618,640.56                        713,907,137.00
    购建固定资产、无形资产和其他
                                     64,716,243.74                         84,913,942.44长期资产支付的现金
    投资支付的现金                 500,000,000.00                        595,000,000.00
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金                                          49,000,000.00
    投资活动现金流出小计                564,716,243.74                        728,913,942.44
    投资活动产生的现金流量净额          -346,097,603.18                       -15,006,805.44三、筹资活动产生的现金流量:
    吸收投资收到的现金                6,157,000.00                        57,414,900.00
    取得借款收到的现金
    发行债券收到的现金
    收到其他与筹资活动有关的现金
    筹资活动现金流入小计                   6,157,000.00                        57,414,900.00
    偿还债务支付的现金
                                                             华兰生物工程股份有限公司 2014 年第三季度报告全文
       分配股利、利润或偿付利息支付
                                                         204,685,848.32                               57,620,480.00的现金
       支付其他与筹资活动有关的现金                          943,200.00
    筹资活动现金流出小计                                     205,629,048.32                               57,620,480.00
    筹资活动产生的现金流量净额                               -199,472,048.32                                -205,580.00四、汇率变动对现金及现金等价物的
                                                              -36,017.24                                 -25,148.49影响
    五、现金及现金等价物净增加额                             -180,579,511.84                            269,691,851.45
       加:期初现金及现金等价物余额                      682,699,844.20                             485,366,547.51
    六、期末现金及现金等价物余额                             502,120,332.36                             755,058,398.96
    法定代表人:安康                      主管会计工作负责人:谢军民                          会计机构负责人:王建体二、审计报告第三季度报告是否经过审计□ 是 √ 否公司第三季度报告未经审计。
                                                                           华兰生物工程股份有限公司
                                                                                董事长:安康
                                                                              2014 年 10 月 31 日
数据加载中...
prevnext
手机查看股票